The abstract is read at the publisher; the summary is JClub's.
ENPP1 expression is significantly upregulated in established osimertinib-resistant NSCLC tumor models, and this elevation is linked to suppression of the cGAS-STING pathway via extracellular cGAMP hydrolysis.
- Why it matters: Acquired EGFR-TKI resistance remains a major clinical problem, and immune checkpoint blockade after resistance has not shown significant survival gains versus chemotherapy.
- What they did: The study used comprehensive transcriptomic analysis of osimertinib-resistant tumor models, then tested ENPP1 depletion or pharmacologic inhibition to assess effects on extracellular cGAMP and immune-cell activation.
- The result: ENPP1 inhibition enhanced immune-cell cytotoxicity and antitumor efficacy in TKI-resistant lung cancers with high ENPP1 expression, and paired clinical samples showed increased ENPP1 after acquired EGFR-TKI resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.